BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26553038)

  • 1. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.
    Madajewski B; Boatman MA; Chakrabarti G; Boothman DA; Bey EA
    Mol Cancer Res; 2016 Jan; 14(1):14-25. PubMed ID: 26553038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced glycometabolism as a mechanism of NQO1 potentiated growth of NSCLC revealed by metabolomic profiling.
    Cheng X; Liu F; Liu H; Wang G; Hao H
    Biochem Biophys Res Commun; 2018 Jan; 496(1):31-36. PubMed ID: 29291405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
    Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
    J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma.
    Shimokawa M; Yoshizumi T; Itoh S; Iseda N; Sakata K; Yugawa K; Toshima T; Harada N; Ikegami T; Mori M
    Cancer Sci; 2020 Apr; 111(4):1228-1240. PubMed ID: 31968140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo.
    Dehn DL; Siegel D; Zafar KS; Reigan P; Swann E; Moody CJ; Ross D
    Mol Cancer Ther; 2006 Jul; 5(7):1702-9. PubMed ID: 16891456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer.
    Liu F; Yu G; Wang G; Liu H; Wu X; Wang Q; Liu M; Liao K; Wu M; Cheng X; Hao H
    PLoS One; 2012; 7(7):e42138. PubMed ID: 22848731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
    Madajewski B; Boatman MA; Martinez I; Carter JH; Bey EA
    Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.
    Zhang X; Bian J; Li X; Wu X; Dong Y; You Q
    Eur J Med Chem; 2017 Sep; 138():616-629. PubMed ID: 28710963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
    Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
    Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
    Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
    J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis.
    Yu J; Zhong B; Zhao L; Hou Y; Ai N; Lu JJ; Ge W; Chen X
    Drug Resist Updat; 2023 Sep; 70():100977. PubMed ID: 37321064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment with highly bioavailable curcumin and NQO1 inhibitor exhibits potent antitumor effects on esophageal squamous cell carcinoma.
    Mizumoto A; Ohashi S; Kamada M; Saito T; Nakai Y; Baba K; Hirohashi K; Mitani Y; Kikuchi O; Matsubara J; Yamada A; Takahashi T; Lee H; Okuno Y; Kanai M; Muto M
    J Gastroenterol; 2019 Aug; 54(8):687-698. PubMed ID: 30737573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells.
    Yu H; Gao HY; Guo H; Wang GZ; Yang YQ; Hu Q; Liang LJ; Zhao Q; Xie DW; Rao Y; Zhou GB
    Acta Pharmacol Sin; 2022 Mar; 43(3):692-702. PubMed ID: 34035487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
    Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
    BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
    Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
    Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1.
    Zheng S; Byrd AS; Fischer BM; Grover AR; Ghio AJ; Voynow JA
    Free Radic Biol Med; 2007 May; 42(9):1398-408. PubMed ID: 17395013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II.
    Wei L; Dai Q; Zhou Y; Zou M; Li Z; Lu N; Guo Q
    Biochim Biophys Acta; 2013 Jun; 1830(6):3835-45. PubMed ID: 23500080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat-induced up-regulation of NAD(P)H:quinone oxidoreductase potentiates anticancer effects of beta-lapachone.
    Park HJ; Choi EK; Choi J; Ahn KJ; Kim EJ; Ji IM; Kook YH; Ahn SD; Williams B; Griffin R; Boothman DA; Lee CK; Song CW
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8866-71. PubMed ID: 16361576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De-novo NAD+ synthesis regulates SIRT1-FOXO1 apoptotic pathway in response to NQO1 substrates in lung cancer cells.
    Liu H; Xing R; Cheng X; Li Q; Liu F; Ye H; Zhao M; Wang H; Wang G; Hao H
    Oncotarget; 2016 Sep; 7(38):62503-62519. PubMed ID: 27566573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement.
    Kim HJ; Lee KY; Kim YW; Choi YJ; Lee JE; Choi CM; Baek IJ; Rho JK; Lee JC
    BMC Cancer; 2015 Jul; 15():553. PubMed ID: 26219569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.